FDA Provides First Known Fast Track Designation for Type 1 Diabetes
FDA Provides First Known Fast Track Designation for Type 1 Diabetes
September 5, 2016Caladrius Biosciences has received FDA orphan drug designation for its CLBS03 therapy for people with type 1 diabetes who still have some residual beta cell function.
Caladrius Biosciences has received FDA orphan drug designation for its CLBS03 therapy for people with type 1 diabetes who still have some residual beta cell function.
Click here to read the full article.